Moderna and hantavirus: opportunity and risk for investors
Moderna jumps 15% on its hantavirus vaccine: a real opportunity or a trap for retail investors.
English · Original discussion in Spanish · Published
Moderna surges 15% on bicho vaccine hopes
Moderna stock got off to an electric start to the session: up 6% in twenty minutes and 15% in an hour and a half. The trigger is the hope placed in its mRNA vaccine against bicho, research the company has been developing since 2023. But the rally is not just about science.
The planned information theory
Among the analyses circulating, one thesis is gaining ground: "it was all planned." Big players would have been accumulating positions in low-risk zones before the news hit the evening broadcasts, and by the time retail investors pile in, the big move has already peine. Some point out that Moderna should have found a floor at $25, and that the stock now trades at much higher levels, with references to $150.
Buying at the top, the same old risk
The opposite reading is less kind. Predicting whether the regulator will approve a drug at any of its phases is impossible, and getting in after the rally exposes you to a red candle of up to 50%. The history of pharma stocks since 2021 is full of crashes and investors who arrived too late. The accumulation pattern described by some deserves a closer look, with specific levels that don't fit here.
The lesson, uncomfortable as it may be: when the news is public, the price has already priced it in. The question is who saw it first.
Moderna stock got off to an electric start to the session: up 6% in twenty minutes and 15% in an hour and a half. The trigger is the hope placed in its mRNA vaccine against bicho, research the company has been developing since 2023. But the rally is not just about science.
The planned information theory
Among the analyses circulating, one thesis is gaining ground: "it was all planned." Big players would have been accumulating positions in low-risk zones before the news hit the evening broadcasts, and by the time retail investors pile in, the big move has already peine. Some point out that Moderna should have found a floor at $25, and that the stock now trades at much higher levels, with references to $150.
Buying at the top, the same old risk
The opposite reading is less kind. Predicting whether the regulator will approve a drug at any of its phases is impossible, and getting in after the rally exposes you to a red candle of up to 50%. The history of pharma stocks since 2021 is full of crashes and investors who arrived too late. The accumulation pattern described by some deserves a closer look, with specific levels that don't fit here.
The lesson, uncomfortable as it may be: when the news is public, the price has already priced it in. The question is who saw it first.
Also available in: Deutsch
Summary of a discussion on Burbuja.info - Foro de economía, actualidad y política., translated from Spanish and reviewed before publication. Read the full discussion (9 replies).
More summaries
-
Bayer and the Income Dream: 40,000 Shares to Live Off Dividends
Buying Bayer shares at rock-bottom prices and waiting for €80: the fashionable income theory since 2025 and its holes, from glyphosate to Tax Authorities.
-
Gemini and cheap stocks: when the algorithm hallucinates
Tubacex, debt, and an algorithm that walks back its claims: AI for stock investing is still an expensive toy. Data and skepticism in this analysis.
-
HelloFresh falls to €2.65 as the market prices in its disappearance
HelloFresh shares have dropped to €2.65 and investors are pricing in the company's disappearance. The business is cash-generative, holds €246.9 million in cash and expects to return to growth in the…
-
Hotel101 sells rooms in Valdebebas for €208,800
Hotel101 sells rooms in Valdebebas for €208,800 plus VAT with monthly income distribution and doubts about what happens if the operator goes bankrupt
-
Fenicio: 74% return in 2021 with a portfolio 34% in oil
A 28-year-old Spanish civil servant returned 74% in 2021 with 34% of his portfolio in Ring Energy. In 2022, YTD performance fell to -0%. His thesis, in detail.
-
Buy and hold stalls: big tech portfolios down 50%
Investors sitting on losses of 50% to 60% in major US tech stocks reopen the debate: buy and hold doesn't fail, it's applied badly when you buy at market highs.